Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Tomosynthese in der Mammadiagnostik (S. 10–18)
Rüdiger Schulz-Wendtland, Matthias W. Beckmann, Peter A. Fasching, M. Uder
Universitätsklinikum Erlangen 

  1. Pisano ED, Gatsonis C, Hendrick E et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2006; 353: 1773–1783
  2. Schulz-Wendtland R, Fuchsjäger M, Wacker T, Hermann KP. Digital mammography: an update. Eur J Radiol 2009; 72: 258–265
  3. Schulz-Wendtland R, Hermann KP, Uder M. Digitale Tomosynthese der Brust. Radiologie up2date 2010; 03: 195–211
  4. Hellerhoff K. Digitale Brusttomosynthese. Der  Radiologe 2010; 50: 991–998
  5. Schulz-Wendtland R, Beckmann MW, Uder M, Fasching PA. Future of mammography-based imaging. Der Radiologe 2014; 54: 217–223
  6. Ziedses des Plantes BG. Eine neue Methode zur Differenzierung in der Röntgenographie (Planigraphie). Acta Radiol 1932; 13: 182–192
  7. Niklason LT, Christian BT, Niklason LE et al. Digital tomosynthesis in breast imaging. Radiology 1997; 205: 399–406
  8. Zhou J, Zhao B, Zhao W. A computer simulation platform for the optimazation of a breast tomosynthesis system. Med Phys 2007; 34: 1098–1112
  9. Mertelmeier T, Ludwig J, Zhao B, Zhao W. Optimazation of tomosynthesis acquisition parameters: angular range and number of projections. Computer Science 2008; 5116: 220–227
  10. Sechopoulus I, Suryanarayanan S, Vedantham S et al. Computation of the glandular dose in digital tomosynthesis of the breast. Med Phys 2007; 34: 221–232
  11. Addendum on Digital Mammography to chapter 2 of the European Guidelines for Quality Assurance in breast cancer screening and diagnosis, European Protocol for the Quality Control of the physical and technical aspects of mammography screening. Fourth edition. Luxembourg: European Commission; 2006
  12. Normenausschuss Radiologie. PAS 1054: Anforderungen und Prüfverfahren für digitale Mammographie-Einrichtungen. Berlin: Beuth Verlag; 2005
  13. Qualitätssicherungs-Richtlinie (QS-RL): Richtlinie zur Durchführung der Qualitätssicherung bei Röntgeneinrichtungen zur Untersuchung oder Behandlung von Menschen nach den §§ 16 und 17 der Röntgenverordnung vom 20. November 2003, zuletzt geändert durch Rundschreiben vom 27. Februar 2008
  14. Normenausschuss Radiologie NAR im DIN Deutsches Institut für Normung e.v. in Arbeitsgemeinschaft mit der Deutschen Röntgengesellschaft. Jahresbericht 2013. Berlin: Beuth Verlag; 2014
  15. Schulz-Wendtland R et al. Experimental phantom lesion detectability study using a digital breast tomosynthesis prototype system. Röfo 2006; 178: 1219–1223
  16. Poplack SP, Tosteson TD, Kogel CA, Nagy HM. Digital breast tomosynthesis: initial experience in 98 women with abnormal digital screening mammography. AJR 2007; 189: 616–623
  17. Good WF, Abrams GS, Catullo VJ et al. Digital breast tomosynthesis: a pilot observer study. AJR 2008; 190: 865–869
  18. Andersson I, Ikeda DM, Zackrisson S et al. Breast tomosynthesis and digital mammography: a comparison of breast cancer visibility and BIRADS classification in a population of cancers with subtle mammmographic findings. Eur Radiol 2008; 18: 2817–2825
  19. Kontos D, Bakic PR, Carton AK et al. Parenchymal texture analysis in digital breast tomosynthesis for breast cancer risk estimation: a preliminary study. Acad Radiol 2009; 16: 283–298
  20. Gur D, Abrams GS, Chough DM et al. Digital breast tomosynthesis: observer performance study. AJR 2009; 193: 586–591
  21. Teertstra HJ, Loo CE, van den Bosch MA et al. Breast tomosynthesis in clinical practice: initial results. Eur Radiol 2010; 20: 16–24
  22. Smith AP, Rafferty EA, Niklason L. Clinical performance of breast tomosynthesis as a function of radiologist experience level. LNCS 2008; 5116: 61–66
  23. Gennaro G, Toledano A, di Maggio C et al. Digital breast tomosynthesis versus digital mammography: a clinical performance study. Eur Radiol 2010 ; 20: 1545–1553
  24. Fömvik D, Zackrisson S, Ljunberg O et al. Breast tomosynthesis: Accuracy of tumor measurement compared with digital mammography and ultrasonography. Acta Radiologica 2010; 51: 240–247
  25. Rose SL et al. Implementation of breast tomosynthesis in a routine screening practice: an observational study. AJR Am J Roentgenol 2023; 200: 1401–1408
  26. Friedewald SM et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 2014; 311: 2499–2507
  27. Ciatto S et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (Storm): a prospective comparison study. Lancet Oncol. 2013; 14: 583–599
  28. Skaane P et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology 2013; 267: 47–-56
  29. Skaane P et al. Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. Eur Radiol 2013; 23: 2061–2071
  30. Skaane P et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: Comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 2014; 271: 655–663
  31. Houssami N et al. Breast screening using 2D-mammography or integrating digital breast tomosynthesis (3D-mammography) for single-reading or double-reading – Evidence to guide future screening strategies. Eur J Cancer 2014; 50: 1799–1807
  32. Chen SC et al. Initial clinical experience with contrast-enhanced digital breast tomosynthesis. Acad Radiol 2007; 14: 229–238
  33. Schmitzberger FF et al. Development of low-dose photon-counting contrast-enhanced tomoynthesis with spectral imaging. Radiology 2011; 259: 558–564
  34. Carton AK et al. Dual-energy contrast-enhanced digital breast tomoynthesis-a feasibility study. Br J Radiol 2010; 83: 344–350
  35. Schrading S et al. Digital breast tomosynthesis-guided vacuum-assisted breast biopsy: initial experiences and comparison with prone stereotactic vacuum assisted biopsy. Radiology 2014; Nov 11:141397
  36. Schulz-Wendtland R, Fasching PA, Beckmann MW, Uder M. Comparison of sonography versus digital breast tomosynthesis to locate intramammary marker clips. Gebfra 2016, in Druck

 

 Systemtherapie beim frühen und beim fortgeschrittenen Mammakarzinom: Standards 2017 (S. 19–25)
Nadia Harbeck, Frauenklinik, Klinikum der Universität München

  1. Perou CM et al Molecular portraits of human breast tumours. Nature 2000 Aug 17; 406(6797): 747–52
  2. Coates AS et al. -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug; 26(8): 1533–46
  3. Gluz O et al. Prospective WSG Phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score® result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2- high risk node-negative and –positive breast cancer patients. EBCC10 Abstr 8LBA, 2016
  4. Sparano JA et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015 Nov 19; 373(21): 2005–14
  5. Cardoso F et al70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375(8): 717–29
  6. Eiermann W et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 2011 Oct 10; 29(29):3877–84
  7. Sparano JA et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 2015 Jul 20; 33(21): 2353–60
  8. Del Mastro L et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2×2 factorial, randomised phase 3 trial. Lancet 2015 May 9; 385(9980): 1863–72
  9. Moebus V et al Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010 Jun 10; 28(17): 2874–80
  10. Pagani O, Regan MM, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014 Oct 2; 371(14): 1358–9
  11. Francis PA et al Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015 Jan 29; 372(5): 436–46
  12. AGO-Kommission “Mamma”. Empfehlungen 2017 für die Behandlung des primären und des metastasierten Mammakarzinoms: www.ago-online.de
  13. Metzger Filho O et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol 2015 Sep 1; 33(25): 2772–9
  14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015 Oct 3; 386(10001): 1341–52
  15. von Minckwitz G et al. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J Clin Oncol 2012; 30(15): 1796–804
  16. von Minckwitz G et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014 Jun; 15(7): 747(suppl; abstr 1005). 56
  17. von Minckwitz G et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. J Clin Oncol 2014;  32(suppl; abstr 1005): 5s
  18. von Minckwitz G et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). SABCS 2015; S2-04
  19. Sikov WM et alEvent-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). SABCS 2015, S2–05
  20. Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015 Jan 8; 372(2): 134–41
  21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015 Oct 3; 386(10001): 1353–61
  22. Gnant M et alAdjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011 Jul; 12(7): 631–41
  23. Gnant M et alAdjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015 Aug 1; 386(9992): 433–43
  24. Finn RS et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016 Nov 17; 375(20): 1925–1936
  25. Cristofanilli M et al.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016 Mar 2.
  26. Hortobagyi GN et alRibociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016 Nov 3; 375(18): 1738–48
  27. Baselga J et al.Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012 Feb 9; 366(6): 520–29
  28. Harbeck N, Gnant M. Breast cancer. Lancet 2017 Mar 18; 389(10074): 1134–50
  29. Miles DW, Diéras V, Cortés J, Duenne AA, Yi J, O'Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013 Nov; 24(11): 2773–80
  30. Swain SM et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015 Feb 19; 372(8): 724–34
  31. Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012 Nov 8; 367(19): 1783–91
  32. Blackwell KL et al Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012 Jul 20; 30(21): 2585–92
  33. Stopeck AT et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010 Dec 10; 28(35): 5132–9
  34. Himelstein AL et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 2017 Jan 3; 317(1): 48–58

Mistel in der Supportivtherapie: Möglichkeiten und Grenzen bei Mammakarzinom (S. 26–28)
Petra Voiss, Klinik für Senologie/Brustzentrum, Essen

  1. Büssing A, Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999 Jan-Feb; 19(1A): 23–8
  2. Kienle GS, Glockmann A, Schink M, Kiene H. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res. 2009 Jun 11; 28:79
  3. Marvibaigi M, Supriyanto E, Amini N, Abdul Majid FA, Jaganathan SK. Preclinical and clinical effects of mistletoe against breast cancer. Biomed Res Int. 2014; 2014: 785479
  4. Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008 Apr 16; (2)
  5. Kienle GS, Glockmann A, Schink M, et al. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 28: 79, 2009
  6. www.onkopedia.com/de/onkopedia/guidelines/mistel-viscum-album/@@view/html/index.html Stand 07/2015
  7. Tröger W, Zdrale Z, Tišma N, Matijašević M. Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial. Evid Based Complement Alternat Med. 2014; 2014: 430518
  8. Tröger W, Jezdić S, Zdrale Z, Tišma N, Hamre HJ, Matijašević M. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer (Auckl). 2009 Jul 6; 3:35–45
  9. Weissenstein U, Kunz M, Urech K, Regueiro U, Baumgartner S. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med. 2016 Aug 4; 16: 271
  10. Weissenstein U, Kunz M, Urech K, Baumgartner S. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complement Altern Med. 2014 Jan 8; 14: 6
  11. Tröger W, Zdrale Z, Stanković N, Matijašević M. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl). 2012; 6:173–80
  12. Ostermann T, Büssing A. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore (NY). 2012 Sep–Oct; 8 (5): 277–81 

Aktuelle Aspekte der rekonstruktiven Mammachirurgie (S. 30–36)
Stefan Paepke, Evelyn Klein, Sissi Dittmer, Arian Rezai, Markus Niemayer, Daniel Müller, Marion Kiechle; Interdisziplinäres Brustzentrum der Technische Universität München 

  1. Rezai M, Krämer S. Targeted Breast Surgery in Breast Cancer Diagnosis and Therapy 9th Duesseldorf Breast Cancer Conference (2012): 13–18
  2. Granitzka S, Siebert W. Onkologische Operationen an der weiblichen Brust. 2. Aufl (2007), Hans Marseille Verlag München
  3. Arbeitsgemeinschaft Gynäkologische Onkologie e.V. Retrieved 2017, from www.ago-online.de
  4. Dieterich M et al. Wie viel Haut kann bei der haut- und nipplesparenden Mastektomie gespart werden, ohne das onkologische Risiko zu erhöhen? gyn (18) 2013: 346–352
  5. Deventer van P, Graewe FR, Würinger E. Improving longevity and results of mastopexy and breast reduction procedures: Reconstruction an internal breast support system with biocompatible mesh to replace the supporting function of the ligamentous suspension. Aesth Plast Surg 2011; DOI 10.1007/s00266-011-9845-2
  6. Bruijn de HP, Johannes S. Mastopexy with 3D preshaped mesh for long term results: development oft he internal bra system. Aesth Plast Chir 2008; DOI 10.1007//s0026-008-9186-y
  7. Gerber B et al. The oncological safety of skin sparing mastectomy with conservation of the nipple areola complex and autologous reconstruction: an extended follow-up study. Ann Surg 2009; 249: 461–8
  8. Brunnert K, Warm M. Technik der Gewebeexpansion in der plastischen Chirurgie. Gynäkol. Praxis 2008; 32: 479–493
  9. Gerber B et al. Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. Ann Surg 2003; 238: 120–7
  10. Paepke S et al. Subcutaneous mastectomy with conservation of the nipple-areola-skin: broadening the indications. Ann Surg 2009;. 250(2): 288–92
  11. Paepke, S. et al. Erfahrungen mit dem Einsatz eines titanisierten Polypropylennetzes in der onkoplastischen Brustchirurgie. gyn Praktische Gynäkologie 2010; 15(3): 150–156
  12. Casella D, Bernini M, Bencini L et al Tiloop®Bra mesh used for immediate breast reconstruction: comparison of retropectoral and subcutaneous implant placement in a prospective single-institution series. Eur J Plast Surg 2014; DOI 10.1007//s00238-014-1001-1
  13. Garvey, P. B. M. D., et al. DIEP and Pedicled TRAM Flaps: A Comparison of Outcomes. Plastic & Reconstructive Surgery 2006; 117(6): 1711–1719
  14. Giunta, R., et al. Behandlung und Ergebnisse von Komplikationen nach freien Lappenplastiken. Handchir Mikrochir plast Chir 2000; 32(03): 176–180
  15. Dieterich, M. and A. Faridi. Biological Matrices and Synthetic Meshes Used in Implant-based Breast Reconstruction – a Review of Products Available in Germany. Geburtshilfe Frauenheilkd 2013; 73 (11): 1100–1106
  16. Paepke, S., et al. Aktuelle Aspekte in der operativen und plastisch-rekonstruktiven Mammachirurgie. Journal Onkologie 2009; (5): 248–250
  17. Klein, E., et al. Einsatz des teilresorbierbaren Zweikomponenten – Polypropylenmeshs SeraGyn BR® für netzgestützte Operationsverfahren in der plastisch-rekonstruktiven Mammachirurgie. Senologie - Zeitschrift für Mammadiagnostik und –therapie 2013; 10: A69
  18. Paepke, S., et al. Einsatz porciner azellulärer Dermis (Strattice ™) als gewebeersetzendes und unterstützendes Interponat zur Implantatabdeckung bei problematischen Weichteilverhältnissen in der plastisch-rekonstruktiven Mammachirurgie. Senologie - Zeitschrift für Mammadiagnostik und –therapie 2012
  19. Rezai A. Inauguraldissertation 2016: Postoperative Komplikationen nach materialunterstützter plastisch-rekonstruktiver Mammaoperationen: Retrospektive Analyse aus dem Interdisziplinären Brustzentrum der Technischen Universität München von 2008–2012
  20. Dittmer S. Inauguraldissertation 2017: Einsatz des teilresorbierbaren Zweikomponenten-Polyprpylennetz
  21. Kim J Y et al. A meta-analysis of human acellular dermis and submuscular tissue expander breast reconstruction. Plastic and reconstructive surgery 2012 Jan; 129: 28
  22. H. Sbitany, J. M. Serletti. Acellular dermis-assisted prosthetic breast reconstruction: a systematic and critical review of efficacy and associated morbidity. Plastic and reconstructive surgery 2011 Dec; 128: 1162
  23. I. C. Hoppe et al. Complications following expander/implant breast reconstruction utilizing acellular dermal matrix: a systematic review and meta-analysis. Eplasty 2011; 11: e40
  24. J. Vardanian et al. Comparison of implant-based immediate breast reconstruction with and without acellular dermal matrix. Plastic and reconstructive surgery 2011 Nov; 128: 403e
  25. A. Jansen, S. A. Macadam. The use of AlloDerm in postmastectomy alloplastic breast reconstruction: part I. A systematic review. Plastic and reconstructive surgery 2011 Jun; 127: 2232
  26. Hester, T. R. J. M. D., et al. Use of Dermal Matrix to Prevent Capsular Contracture in Aesthetic Breast Surgery. Plastic & Reconstructive Surgery 2012; 130(5S-2): 126S–136S
  27. T. T. Nyame, K. P. Lemon, R. Kolter, E. C. Liao. High-throughput assay for bacterial adhesion on acellular dermal matrices and synthetic surgical materials. Plastic and reconstructive surgery 2011 Nov; 128: 1061
  28. Gschwantler-Kaulich D, Schrenk P, Bjelic-Radisic V et al. Mesh versus acellular dermal matrix in immediate implant-based breast reconstruction – A prospective randomized trial. EJSO 2016
  29. Dieterich M, Paepke S, Zwiefel K et al.  Implant-based breast reconstruction using a titanium-coated polypropylene mesh (TiLOOP Bra): a multicenter study of 231 cases. Plastic and Reconstructive Surgery 2013; 132(1): 8e–19e
  30. AGO-Leitlinie. Version 2011. http//www.ago-online.deAGO-Leitlinien.
  31. Albornoz, C. R. M. D. M. S., et al. A Paradigm Shift in U.S. Breast Reconstruction: Increasing Implant Rates. Plastic & Reconstructive Surgery 2013; 131(1): 15–23
  32. Albornoz, C. R. M. D. M. S., et al. Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer: The Role of Breast Reconstruction. Plastic & Reconstructive Surgery 2015; 135(6): 1518–1526
     

VERSORGUNGSFORSCHUNG
Qualitätsindikatoren in der Onkologie
(S. 52–53)
Thomas Langer, Simone Wesselmann, Christoph Kowalski; Deutsche Krebsgesellschaft e. V., Berlin

  1. Bundesanzeiger. Gesetz zur Reform der Strukturen der Krankenhausversorgung (Krankenhausstrukturgesetz–KHSG). 2015  [cited 2017 18.04.]; Available from: www.bgbl.de/xaver/bgbl/start.xav
  2. Qualitätsindikatoren. Manual für Autoren. 3 ed, ed. M. Zentralstelle der Deutschen Ärzteschaft zur Qualitätssicherung in der. Vol. 36. 2009, Berlin: Schriftenreihe ÄZQ
  3. Donabedian, A., Evaluating the quality of medical care. Milbank Mem.Fund Q., 1966. 44: p. 166–206
  4. Hermes-Moll, K., et al., WINHO-Qualitätsindikatoren für die ambulante onkologische Versorgung in Deutschland. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2013. 107(8): p. 548–559
  5. Nothacker, M., C. Muche-Borowski, and I.B. Kopp, [Measuring quality in the German Guideline Programme in Oncology (GGPO)-methodology and implementation]. Z Evid Fortbild Qual Gesundhwes, 2014. 108(8-9): p. 470–80
  6. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft (DKG), D.K.D., Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)), Entwicklung von Leitlinien basierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie. Version 2.0.2017. 2017, Berlin
  7. Wolff, K.D., et al., Effect of an evidence-based guideline on the treatment of maxillofacial cancer: A prospective analysis. J Craniomaxillofac Surg, 2017. 45(3): p. 427–431
  8. Follmann, M., et al. Updating Guideline based Quality Indicators. The Methodology of the German Breast Cancer Guideline Development Group. in Guidelines International Network. G-I-N Conference 2012. 2012. Berlin: German Medical Science GMS Publishing House
  9. Blum, T., et al., Erste praktische Erfahrungen bei der routinemäßigen Erfassung der Qualitätsindikatoren der S3-Leitlinie Lungenkarzinom mit altem und neuem TNM-System. Pneumologie, 2011. 65(S 01): p. P427
     

PHARMAFORUM
Halaven® (Eribulin) beim fortgeschrittenen Mammakarzinom:
Klinische Daten weisen auf eine anti-metastasierende Wirkung von Eribulin hin (S. 56–57)

  1. Fachinformation HALAVEN®, Stand August 2016
  2. Dybdal-Hargreaves NF et al. SABCS 2015; Poster P5-03-09
  3. Rohena CC et al. SABCS 2015; Poster P5-03-08
  4. Yoshida T et al. Br J Cancer 2014; 110: 1497–1505
  5. Utsumi T et al. SABCS 2016, Poster#: P5-15–10
  6. Cortes J et al. Lancet. 2011; 377: 914–923
  7. Kaufman PA et al. J Clin Oncol 2015; 33: 594–601
  8. Twelves C et al. Breast Cancer 2016; 10: 77–84
  9. Schöffski P et al. Lancet 2016; 387(10028): 1629–37